Search this site
Skip to main content
Skip to navigation
Joshua Joel SMA Life Foundation
HOME
SPINAL MUSCULAR ATROPHY
SMA and Genetics
Testing & Diagnosis
Resource(s) for Medical Professionals and Scientists
Potential Complications of SMA
ABOUT JOSHUA
OUR PURPOSE
CONTACT US
MAILING LIST
JOSHUA'S JOURNEY BLOG
Belk CharitySale
Birthday celebration
Happy New Year
Happy Thanksgiving
Happy Veteran's Day
Joshua Fletcher Sunset
Joshua Turns FIVE
Joshua's Eyes Says It All
JOSHUA'S JOURNEY WITH SMA
JOSHUA'S VIDEOS
Merry Christmas
Still Here By the Grace of God
Thank You
Thank You Belk
Thank You Children's Home Society
Thank You for Supporting our 2nd Annual Raffle
Thank You to Genius Entertainment
Thank You to Gift Certificates and More
Tribute to Dr. Carla Phillips
Win A Play Station 4
PRESS RELEASE
For kids in need, a gift of donated video game fun
Give6 Article Published by World News
Give6 Making a Difference GTN News
Give6’s Video Game Drive Official Launch and Ribbon Cutting
Video-game drive helps raise awareness, support for little-known disease
NEWS AND ANNOUNCEMENTS
2009 Families of SMA Conference
A case of spinal muscular atrophy type 0 in Japan.
A new approach to spinal muscular atrophy?
Candidate Drug Provides Benefit in Spinal Muscular Atrophy Animal Models
Families of Spinal Muscular Atrophy Announces $700,000 Funding for Novel Drug Program at Newly Created California Institute for Biomedical Research
Hans Keirstead: Developing therapies based on embryonic stem cells
Hypoxia is a modifier of SMN2 splicing and disease severity in a severe SMA mouse model.
Impaired Mitochondrial Dynamics Play Role in SMA Pathology
In Spinal Muscular Atrophy, Vascular System May Play a Key Role
Isis Pharmaceuticals Announces Open-Label Extension Study SHINE in Pediatric SMA Patients
Key SMA Patient Trial of Skeletal Muscle Activator Getting Underway
NIH Provides Congress an Overview of the Federal Government’s Spinal Muscular Atrophy Research Activities.
Possible Cause of Movement Defects in Spinal Muscular Atrophy Identified
Potential SMA Therapy Ready for a First Clinical Test
President Obama Signs Into Law a Bill to Expedite FDA Approval of Drugs for Rare Diseases.
Repligen Initiates Phase 1b Trial of RG3039 for Spinal Muscular Atrophy Licensed from Families of SMA.
Repligen Reports Positive Results from Phase 1 Clinical Trial of RG3039 for Spinal Muscular Atrophy
Research Suggests New Cause to Blame for Spinal Muscular Atrophy
Scientists measure communication between stem cell-derived motor neurons and muscle cells
SMA News 2009
SMA News 2010
SMA News 2011
SMA: Trial Tests Antisense Therapy in Infants
Spinal Muscular Atrophy Study Points to Blood Vessel Defects
Valproic Acid blocks Excitability in SMA Type I Mouse Motoneurons.
Programs
GIVE6 VIDEO GAME DRIVE
2015 GIVE6 VIDEO GAME DRIVE
2015 FREQUENTLY ASKED QUESTIONS
2015 SPONSORSHIP
2015 VIDEO GAME APPLICATION
2014 GIVE6 VIDEO GAME DRIVE
2014 GIVE6 VIDEO GAME DRIVE
2014 GIVE6 VIDEO GAME DRIVE PARTNERS
APPLICATION VIDEO GAMES DRIVE 2014
FREQUENTLY ASKED QUESTIONS
GIVE-6 BACKGROUNDER
SPONSORSHIP
Forever Light
2017 FOREVER LIGHT WALK
SMA LINKS
PRIVACY STATEMENT
Joshua Joel SMA Life Foundation
Give6 Article Published by World News
Post date: Jul 1, 2014 2:29:44 AM
Google Sites
Report abuse
Google Sites
Report abuse
